Sanofi: Q3 turnover up 16 per cent and profit of 3.03 billion; revises guidance upwards

(Il Sole 24 Ore Radiocor) - Sanofi closed the third quarter of 2026 with net turnover of €14.44 billion, up by over 16 per cent compared with the same period in 2025 (+14.3 per cent at constant exchange rates), operating profit of €4.35 billion (compared with €3.62 billion last year) and net profit of €3.03 billion, up from €2.81 billion in 2025. The increase in turnover “was driven mainly by our new medicines and by Dupixent”, explains CEO Belen Garijo.

The pharmaceutical giant has revised its guidance for 2026 upwards and now forecasts revenue growth “in the lower single-digit range” and earnings per share growth – which stood at €3.55 in the third quarter – “in the mid-single-digit range”.

Vec

The latest Radiocor videos